CIK 0001124105
- Accelerated filer
- Smaller reporting company
GYRE THERAPEUTICS, INC.
Sign in to watch- Ticker
- GYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 562020050
- Phone
- +1 858-284-0115
- Business address
- 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
- Former names
- CATALYST BIOSCIENCES, INC., TARGACEPT INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-06-09 | USMAN NASSIM President and CEO | Other acquisition · Stock Option (Right to Buy) | +0 | 0 | ||
| 2016-06-09 | USMAN NASSIM President and CEO | Grant or award · Stock Option (Right to Buy) | +7,500 | 7,500 | ||
| 2016-06-09 | SELICK HAROLD E Director | Grant or award · Stock Option (Right to Buy) | +7,500 | 7,500 | ||
| 2016-06-09 | Richard John P Director | Grant or award · Stock Option (Right to Buy) | +7,500 | 7,500 | ||
| 2016-06-09 | LAWLOR AUGUSTINE Director | Grant or award · Stock Option (Right to Buy) | +7,500 | 7,500 | ||
| 2016-06-09 | HILL STEPHEN A Director | Grant or award · Stock Option (Right to Buy) | +7,500 | 7,500 | ||
| 2016-06-09 | DESOUZA ERROL B Director | Grant or award · Stock Option (Right to Buy) | +7,500 | 7,500 | ||
| 2016-04-18 | Levy Howard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2015-12-17 | USMAN NASSIM President & CEO | Purchase | +4,000 | $2.00 | $8K | 78,375 |
| 2015-12-17 | Payne Fletcher Chief Financial Officer | Purchase | +10,000 | $2.00 | $20K | 25,032 |
| 2015-12-17 | HILL STEPHEN A Director | Purchase | +5,000 | $2.03 | $10K | 20,711 |
| 2015-10-22 | USMAN NASSIM President & CEO | Grant or award · Stock Option (Right to Buy) | +153,572 | 153,572 | ||
| 2015-10-22 | SELICK HAROLD E Director | Grant or award · Stock Option (Right to Buy) | +6,750 | 6,750 | ||
| 2015-10-22 | Richard John P Director | Grant or award · Stock Option (Right to Buy) | +6,750 | 6,750 | ||
| 2015-10-22 | Payne Fletcher Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +28,572 | 28,572 | ||
| 2015-10-22 | Madison Edwin Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +58,572 | 58,572 | ||
| 2015-10-22 | LAWLOR AUGUSTINE Director | Grant or award · Stock Option (Right to Buy) | +6,750 | 6,750 | ||
| 2015-10-22 | HILL STEPHEN A Director | Grant or award · Stock Option (Right to Buy) | +6,750 | 6,750 | ||
| 2015-10-22 | DESOUZA ERROL B Director | Grant or award · Stock Option (Right to Buy) | +6,750 | 6,750 | ||
| 2015-10-22 | LAWLOR AUGUSTINE Director | Grant or award · Stock Option (Right to Buy) | +8,250 | 8,250 |
Page 23 of 24 · 471 trades